A Phase II Study of LN-145 Immunotherapy in People with Metastatic Non-Small-Cell Lung Cancer

Full Title

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Purpose

The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called “autologous tumor infiltrating lymphocytes” (TIL) therapy. It activates white blood cells to attack the tumor.

TIL therapies are made in a laboratory from white blood cells called lymphocytes (T cells) that are collected from a patient’s tumor. Patients in this study will have T cells removed from their tumors to make the treatment and will receive intravenous chemotherapy (by vein) to prepare them for the treatment. They will then receive LN-145 intravenously.